ArticleCrohn's & colitis 3602020

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease.

Anand Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.